Loading...
XNAS
GNPX
Market cap920kUSD
Jul 09, Last price  
0.56USD
1D
-1.49%
1Q
-51.70%
IPO
-99.99%
Name

Genprex Inc

Chart & Performance

D1W1MN
XNAS:GNPX chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
120.83%
Rev. gr., 5y
%
Revenues
0k
Net income
-16m
L-23.13%
-1,069,722-4,132,159-3,314,157-12,372,339-10,654,768-17,942,770-20,664,969-23,740,621-30,860,461-21,111,163-16,228,953
CFO
-15m
L-10.72%
-688,261-1,248,263-2,171,594-6,846,534-6,918,721-13,935,086-14,284,924-17,778,964-24,738,603-17,149,088-15,311,209

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
IPO date
Mar 29, 2018
Employees
30
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT